NMN (Nicotinamide Mononucleotide)
coenzymeAlso known as: Nicotinamide Mononucleotide, beta-NMN, NAD+ Precursor
About
NMN is a direct precursor to NAD+, a critical coenzyme for mitochondrial energy metabolism and sirtuin-mediated cellular repair. NAD+ levels decline approximately 50% between ages 40-60, correlating with cardiovascular aging. A 2024 RCT showed NMN at 250 mg/day improved arterial stiffness and reduced aortic pulse wave velocity in middle-aged adults.
How It Works
Direct precursor to NAD+ (nicotinamide adenine dinucleotide), a critical coenzyme for mitochondrial energy metabolism, sirtuin-mediated DNA repair, and PARP-mediated stress response; supports endothelial function by restoring SIRT1 activity in vascular smooth muscle; activates AMPK improving metabolic health markers associated with cardiovascular risk.
Evidence For Conditions
| Condition | Grade | Studies | Participants | |
|---|---|---|---|---|
| Arterial Stiffness | C | 2 | 100 | View → |
| Heart Failure | D | 0 | -- | View → |
Side Effects
- Generally well-tolerated
- Mild gastrointestinal discomfort
- Flushing (rare)
- Headache (rare)
Drug & Supplement Interactions
- May interact with NAD+-dependent medications
- Theoretical interaction with diabetes medications (may affect glucose metabolism)
Always inform your healthcare provider about all supplements you take.
Related Ingredients
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.